Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II).

scientific article published on 27 June 2007

Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S00392-007-0540-X
P698PubMed publication ID17593313

P50authorWolfgang KoenigQ20172819
P2093author name stringR Müller
C Müller
M Möckel
R Dietz
T Störk
R Gareis
O Danne
J O Vollert
P2860cites workLipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial InfarQ46990506
Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay meQ47829708
Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18.Q48329269
Release pattern of N-terminal pro B-type natriuretic peptide (NT-proBNP) in acute coronary syndromes.Q48591877
Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptideQ48630098
Models for diagnosing chest pain: is CART helpful?Q52267061
Association between Lp-PLA2 and coronary artery disease: Focus on its relationship with lipoproteins and markers of inflammation and hemostasisQ57192508
Lipoprotein-Associated Phospholipase A 2 , Platelet-Activating Factor Acetylhydrolase, Is Expressed by Macrophages in Human and Rabbit Atherosclerotic LesionsQ59704158
Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolaseQ69614163
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study GroupQ73088406
Predictive factors of restenosis after coronary stent placementQ73857145
Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery diseaseQ73901926
Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of CardiologyQ74205749
Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasmaQ78056182
Evaluation of coagulation markers for early diagnosis of acute coronary syndromes in the emergency roomQ78448050
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevationQ78722335
B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudyQ80356150
The TIMI Risk Score for Unstable Angina/Non–ST Elevation MIQ22252998
Atherosclerosis — An Inflammatory DiseaseQ26776972
Future biomarkers for detection of ischemia and risk stratification in acute coronary syndromeQ28240315
Platelet-activating factor acetylhydrolasesQ28243333
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in womenQ29616306
Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a reviewQ30826404
Present treatment of acute myocardial infarction in patients over 75 years--data from the Berlin Myocardial Infarction Registry (BHIR).Q31043179
Modified LDL - trigger of atherosclerosis and inflammation in the arterial intimaQ33890396
Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarctionQ33917874
ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice gQ34154695
Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic targetQ34443175
Lp-PLA2: an emerging biomarker of coronary heart diseaseQ34606938
Platelet-activating factor acetylhydrolase (PAF-AH).Q34619701
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolaseQ35062409
Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular diseaseQ35178997
A systematic review of the diagnostic accuracy of natriuretic peptides for heart failureQ35914841
Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery diseaseQ38410603
Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern GQ40479587
Liver cells secrete the plasma form of platelet-activating factor acetylhydrolaseQ41887100
Lipoprotein-associated PLA2 inhibition--a novel, non-lipid lowering strategy for atherosclerosis therapyQ43604021
Human macrophages secret platelet-activating factor acetylhydrolaseQ43778334
N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromesQ44446907
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) studyQ44752425
Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-upQ45200533
C-reactive protein levels and outcomes after statin therapyQ45213511
Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam StudyQ45256250
Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudyQ45263389
Role of N-terminal pro-B-type natriuretic peptide in risk stratification in patients presenting in the emergency roomQ46668016
Acute coronary syndromes without ST-segment elevation--what is the role of early intervention?Q46703406
P433issue9
P921main subjectlipoproteinQ28350
acute coronary syndromeQ266018
P304page(s)604-612
P577publication date2007-06-27
P1433published inClinical Research in CardiologyQ2665050
P1476titleLipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II).
P478volume96

Reverse relations

cites work (P2860)
Q37148410A cross-sectional study of intima-media thickness, ethnicity, metabolic syndrome, and cardiovascular risk in 2268 study participants
Q42471464Altered nitric oxide/cGMP platelet signaling pathway in platelets from patients with acute coronary syndromes
Q26853640Can lipoprotein-associated phospholipase A2 be used as a predictor of long-term outcome in patients with acute coronary syndrome?
Q44015753Coronary surgery for acute coronary syndrome: which determinants of outcome remain?
Q37994308Developing and assessing cardiovascular biomarkers
Q35059506Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study
Q39912642Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease
Q33536648Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature
Q37445865Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target
Q37729873Lipoprotein-associated phospholipase A2: a new therapeutic target.
Q33764961Lipoprotein-associated phospholipase-A2 activity and its diagnostic potential in patients with acute coronary syndrome and acute ischemic stroke.
Q33664272Lp-PLA2 Inhibition-The Atherosclerosis Panacea?
Q36145180Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2
Q38138969Perspectives on the value of biomarkers in acute cardiac care and implications for strategic management
Q36913018Predicting the risk of cardiovascular disease: where does lipoprotein-associated phospholipase A(2) fit in?
Q35764402Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis
Q37902963The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk
Q83474563[Cardiac biomarkers in the critically ill]

Search more.